1. Home
  2. IMNM vs BCC Comparison

IMNM vs BCC Comparison

Compare IMNM & BCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

N/A

Current Price

$28.01

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Logo Boise Cascade L.L.C.

BCC

Boise Cascade L.L.C.

HOLD

Current Price

$82.24

Market Cap

2.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
BCC
Founded
2006
2004
Country
United States
United States
Employees
N/A
7680
Industry
Medicinal Chemicals and Botanical Products
RETAIL: Building Materials
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
IMNM
BCC
Price
$28.01
$82.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
5
Target Price
$32.80
$99.20
AVG Volume (30 Days)
1.1M
315.0K
Earning Date
05-08-2026
05-04-2026
Dividend Yield
N/A
1.11%
EPS Growth
51.40
N/A
EPS
N/A
2.11
Revenue
$6,941,000.00
$4,995,290,000.00
Revenue This Year
N/A
$3.41
Revenue Next Year
$1,127.34
$4.76
P/E Ratio
N/A
$39.09
Revenue Growth
N/A
12.71
52 Week Low
$8.67
$65.00
52 Week High
$30.06
$91.97

Technical Indicators

Market Signals
Indicator
IMNM
BCC
Relative Strength Index (RSI) 62.76 52.78
Support Level $18.72 $71.52
Resistance Level N/A $87.75
Average True Range (ATR) 1.51 2.34
MACD 0.15 -0.48
Stochastic Oscillator 66.25 27.81

Price Performance

Historical Comparison
IMNM
BCC

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About BCC Boise Cascade L.L.C.

Boise Cascade Co is a producer of engineered wood products (EWP) and plywood. The firm operates in two reportable segments, namely Wood Products and Building Materials Distribution. The Wood Products segment manufactures laminated veneer lumber (LVL), I-joists, and laminated beams. In addition, it manufactures structural, appearance, and industrial-grade plywood panels, and ponderosa pine lumber. The Building Materials Distribution segment is engaged in the distribution of various building materials, including oriented strand board (OSB), plywood, and lumber; general line items such as siding, composite decking, doors and millwork, metal products, roofing, and insulation; and EWP, among others. The company generates a majority of its revenue from the Building Material Distribution segment.

Share on Social Networks: